Dr. Thomas Tobin

On Friday--the final day of the National HBPA Conference at Prairie Meadows--a panel entitled "Establishing No-Effect Thresholds and the Importance for the Industry" was led by practicing equine veterinarian and researcher Dr. Clara Fenger. She cited the Horseracing Integrity & Safety Authority's enabling legislation that HISA-covered horses "should compete only when they are free from the influence of medications ..." (her emphasis added). Fenger's point: Testing many substances to limit of detection--if the lab can find it, it's a violation, no matter how tiny the amount and whether it impacts...

Scientifically-based screening levels and transparency in how policy is made were among key items addressed in the Kent Stirling Memorial Medication Panel, held during Wednesday's second day of the National Horsemen's Benevolent & Protective Association conference at the Hotel Monteleone. The National HBPA has long advocated for scientifically-developed screening and threshold levels used to determine if a positive finding is a legitimate rules violation, or if a negligible amount was inadvertently transferred to a horse or by contamination with no pharmacological impact on the animal's performance. The topic comes to...